Show simple item record

dc.contributor.authorStadtmauer, E. A.
dc.contributor.authorSullivan, K. M.
dc.contributor.authorEl Idrissi, M.
dc.contributor.authorSalaun, B.
dc.contributor.authorAlonso Alonso, A.
dc.contributor.authorAndreadis, C.
dc.contributor.authorAnttila, V. J.
dc.contributor.authorBloor, Adrian
dc.contributor.authorBroady, R.
dc.contributor.authorCellini, C.
dc.contributor.authorCuneo, A.
dc.contributor.authorDagnew, A. F.
dc.contributor.authorDi Paolo, E.
dc.contributor.authorEom, H.
dc.contributor.authorGonzález-Rodríguez, A. P.
dc.contributor.authorGrigg, A.
dc.contributor.authorGunther, A.
dc.contributor.authorHeineman, T. C.
dc.contributor.authorJarque, I.
dc.contributor.authorKwak, J. Y.
dc.contributor.authorLucchesi, A.
dc.contributor.authorOostvogels, L.
dc.contributor.authorPolo Zarzuela, M.
dc.contributor.authorSchuind, A. E.
dc.contributor.authorShea, T. C.
dc.contributor.authorSinisalo, U. M.
dc.contributor.authorVural, F.
dc.contributor.authorYáñez San Segundo, L.
dc.contributor.authorZachée, P
dc.contributor.authorBastidas, A.
dc.date.accessioned2021-09-07T13:16:14Z
dc.date.available2021-09-07T13:16:14Z
dc.date.issued2021en
dc.identifier.citationStadtmauer EA, Sullivan KM, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Human Vaccines & Immunotherapeutics. 2021 Aug 18;1–11.en
dc.identifier.pmid34406911en
dc.identifier.doi10.1080/21645515.2021.1953346en
dc.identifier.urihttp://hdl.handle.net/10541/624527
dc.description.abstractImmunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50-70 days post-auHSCT, followed by the second dose at 1-2 months (M) later. In cohorts of 114-1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18-49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBCL) patients, CD4[2+] T-cell frequencies were similar between NHBCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBCL patients despite the lower humoral response.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1080/21645515.2021.1953346en
dc.titleAdjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practiceen
dc.typeArticleen
dc.contributor.departmentUniversity of Pennsylvania, Philadelphia, PA, USAen
dc.identifier.journalHuman Vaccines and Immunotherapeuticsen
dc.description.noteen]
refterms.dateFOA2021-09-08T13:02:35Z


Files in this item

Thumbnail
Name:
34406911.pdf
Size:
5.596Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record